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Diamond-Blackfan anemia (DBA) is a rare, pure red-cell aplasia that presents during infancy. Approximately 40% of cases are
associated with other congenital defects, particularly malformations of the upper limb or craniofacial region. Mutations in the
gene coding for the ribosomal protein RPS19 have been identiﬁed in 25% of patients with DBA, with resulting impairment of 18S
rRNA processing and 40S ribosomal subunit formation. Moreover, mutations in other ribosomal protein coding genes account for
about 25% of other DBA cases. Recently, the analysis of mice from which the gene coding for the heme exporter Feline Leukemia
Virus subgroup C Receptor (FLVCR1) is deleted suggested that this gene may be involved in the pathogenesis of DBA. FLVCR1-
null mice show a phenotype resembling that of DBA patients, including erythroid failure and malformations. Interestingly, some
DBA patients have disease linkage to chromosome 1q31, where FLVCR1 is mapped. Moreover, it has been reported that cells
from DBA patients express alternatively spliced isoforms of FLVCR1 which encode non-functional proteins. Herein, we review the
k n o w nr o l e so fR P S 1 9a n dF L V C R 1i nr i b o s o m ef u n c t i o na n dh e m em etabolism respectively, and discuss how the deﬁciency of a
ribosomal protein or of a heme exporter may result in the same phenotype.
1.Introduction
Diamond Blackfan anemia (DBA; OMIM #205900) is a
rare, congenital, pure red-cell aplasia that presents during
infancy, usually within the ﬁrst year of life. Its main clinical
features are normochromic and macrocytic anemia, reticu-
locytopenia, and nearly complete absence of red blood cell
precursors in the bone marrow. The erythroid hypoplasia is
duetoimpairedproliferationanddiﬀerentiationofredblood
cell progenitors in the bone marrow. Other hematopoietic
lineages are usually normal. High serum levels of folic
acid,vitaminB12,erythropoietin,elevatedfetalhemoglobin,
and erythrocyte adenosine deaminase further support DBA
diagnosis [1].
DBA is a clinically heterogeneous disorder. In addition to
erythroid failure, it is also characterized by congenital mal-
formations and cancer predisposition. Growth retardation
and a wide variety of congenital anomalies have been seen in
more than 50% of DBA cases. Short stature is constitutional
in most patients. Thumbs, upper limbs, and hands and
craniofacial, urogenital, and cardiovascular anomalies are
also common. Although not yet statistically validated, DBA
patients have an increased risk of cancer development.
Both hematopoietic malignancy (acute myeloid leukemia,
myelodysplastic syndrome, Hodgkin and non/Hodgkin lym-
phomas, and acute lymphoblastic leukemia) and non-
hematopoietic tumors (osteogenic sarcoma, breast can-
cer,hepatocellularcarcinoma,melanoma,ﬁbrohistiocytoma,
gastric cancer, and colon cancer) have been described in
some DBA patients [2, 3].
DBA is an autosomal dominant disorder with a disease
incidence of 5–10 cases per million live births in Europe.
The molecular genetics of DBA is evident in about half of
the patients. All the DBA mutations identiﬁed so far, both
in sporadic and familial cases, have been found in genes
coding for ribosomal proteins, and DBA is now considered
the prototype of “ribosome-based disorders”. The ﬁrst DBA
gene to be identiﬁed is Ribosomal Protein S19 (RPS19),
located on chromosome 19q13.2 and mutated in 25% of
DBApatients.Recently,mutationsinseveralotherribosomal2 Advances in Hematology
proteins, RPS24, RPS17, RPL11, RPL5, RPS7, and RPL35a,
have been identiﬁed in approximately 20% of DBA patients
[4]. In the remaining 55% of DBA patients, no mutations
have been reported suggesting the existence of other genes
involved in the pathogenesis of DBA.
Recently, it has been demonstrated that Feline Leukemia
Virus subgroup C Receptor (FLVCR1) deﬁcient embryos
display a phenotype very close to DBA patients, including
bone marrow failure and congenital malformations [5].
FLVCR1 is a heme exporter [6, 7] suggesting that altered
heme homeostasis could play a fundamental role in the
pathogenesis of DBA. Although no mutations in FLVCR1
have been found in DBA patients [8], it will be interesting
to understand how the deﬁciency in a heme exporter
could recapitulate the human disease and if a link between
FLVCR1 and the ribosome biosynthetic pathway exists. In
this paper, the possible molecular mechanisms underlying
the pathogenesis of DBA are discussed.
2. Diamond-Blackfan Anemia as a Disorder of
Ribosome Biogenesis
2.1. Ribosomal Protein S19. RPS19 is one of 33 ribosomal
proteins that, together with 18S rRNA, constitute the 40S
ribosomal subunit. Immunoelectron microscope studies
showed that it localizes to the external surface of the 40S
subunit, in close proximity to RPS3A, RPS13, RPS16, and
RPS24, a region that interacts with the eukaryotic initiation
factor eIF-2 [9].
RPS19 is a highly conserved, ubiquitously expressed pro-
tein. In red blood cells, RPS19 expression strongly decreases
during terminal erythroid diﬀerentiation [10]. RPS19 is
localized predominantly in the nucleus, in particular into the
nucleolus where ribosome synthesis takes place, and in the
cytoplasm as a ribosomal component [11].
Diﬀerent kinds of mutation in RPS19 have been discov-
ered in DBA patients: nonsense and missense mutations,
deletions, insertions, splice defects, and larger rearrange-
ments. RPS19 mutations could lead to reduction of mRNA
and/or protein levels, loss of nucleolar localization, or
impairment of ribosomal association [12]. All the mutations
identiﬁed so far in ribosomal proteins have been found in
heterozygosity. How the haploinsuﬃciency of a ribosomal
protein may lead to erythroid failure, malformations, and
cancer is still not completely understood and the multiple
molecular mechanisms in which ribosomal proteins are
involved are only just becoming clearer.
2.2. In Vitro and In Vivo Models of RPS19 Deﬁciency. The
erythroid hypoplasia characterizing DBA is due to a defect
oferythroidprogenitordiﬀerentiation.CD34+bonemarrow
cells derived from DBA patients and cultured in vitro show
a reduction in proliferation rates and colony formation
capacity associated with increased apoptosis [13, 14].
The fact that RPS19 has a fundamental role during
erythropoiesis was ﬁrst evident when RPS19 mutations were
identiﬁed in DBA patients. This role was further conﬁrmed
by in vitro studies in which the eﬀect of RPS19 silencing
and overexpression was analyzed. In both primary culture
(CD34+ umbilical cord blood and bone marrow cells)
and erythroid-like cell lines (TF-1 and U-7 cells) RPS19
silencing mimics the DBA phenotype: impaired erythroid
diﬀerentiation and proliferation of erythroid progenitors,
cell growth arrest at G0/G1, and apoptosis [13, 15]. Similar
results were obtained by overexpressing mutated forms of
RPS19, analogous to those found in DBA patients, in K562
cells and in human CD34+ bone marrow cells [16]. On the
contrary, RPS19 overexpression into CD34+ bone marrow
cells from RPS19-deﬁcient DBA patients increases the ery-
throid colony formation capacity and improves erythroid
progenitors proliferation in vitro [17–19]. Furthermore, the
loss of diﬀerent ribosomal proteins causes diﬀerent cell cycle
defects; primary ﬁbroblast from DBA patients with RPS19
mutations is characterized by cell cycle arrest at the G1 phase
while RPS24 mutation impairs the progression through the S
phase [20].
Generation of a mouse model of RPS19 deﬁciency has
been attempted by Matsson and colleagues but the deletion
of RPS19 in mice is lethal before implantation; no RPS19
deﬁcient embryo may be recovered as early as the blasto-
cyst stage. Moreover, RPS19 heterozygous mice are viable
but indistinguishable from wild-type mice: hematological
parameters, erythroid proliferation, and diﬀerentiation are
normal as well as organ development and morphology. No
diﬀerence may be found in DBA markers such as erythrocyte
adenosine deaminase and globin isoforms. Contrary to
the occurrence in human patients, heterozygous mice fully
compensate the loss of one RPS19 allele with normal protein
levels [21, 22].
On the other hand, zebraﬁsh appears to be a good
animal model to study the consequences of RPS19 deﬁ-
ciency. Knocking-down RPS19 in zebraﬁsh, using antisense
morpholinos, perfectly recapitulates the DBA phenotype.
Both the primitive and deﬁnitive waves of erythropoiesis
are impaired: an increased number of red cell progenitors
remains in the intermediate cell mass and primitive cells
are not replaced by adult ones. Also erythroid markers of
diﬀerentiation, such as gata-1 and c-myb, are expressed at
lower levels compared to controls. Myeloid and lymphoid
lineages appear normal. Morphants also show delayed devel-
opment and morphological defects that are evident during
somatogenesis: reduced forebrain and eye ﬁeld, smaller head
a n de y e sw i t hh e a dc a r t i l a g en o tf o r m e dp r o p e r l y[ 23–
25]. Similar phenotypes are observed when the expression
of other ribosomal proteins is lost. The knock-down of
RPL35, RPL35a, and RPLP2 in zebraﬁsh leads to erythroid
failure and malformations [24], while the loss of RPL11 only
leads to alteration of embryonic development [26]. These
data highlight an important role for ribosomal proteins
not only during erythropoiesis but also for proper organ
development.
The fundamental role of ribosome integrity for ery-
thropoiesis and development is further conﬁrmed by the
observationthataheterogeneousgroupofdisorders,referred
to as “inherited bone marrow failure syndromes”, is also
characterized by bone marrow failure, congenital malfor-
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this group of disorders include dyskeratosis congenita (DC),
cartilage-hairhypoplasia(CHH),andShwachman-Diamond
syndrome (SDS). In each case, a defect in proteins that
are involved in ribosome synthesis has been identiﬁed. DC
is due to mutations in dyskerin gene (DKC1), a puta-
tive pseudouridyl synthase involved in rRNA modiﬁcation.
Mutations in RMPR, which encode the RNA component
of ribonuclease mitochondrial RNA processing complex
(RNase MRP), involved in the cleavage of rRNA precursors
andotherfunctions,havebeenidentiﬁedinCHH.SDSisdue
tomutationsinSBDS,whichencodeforaproteininvolvedin
ribosome synthesis [1].
2.3. Role of RPS19 in Ribosome Biogenesis. The mammalian
ribosome is composed of a large 60S and a small 40S
subunit consisting of 4 rRNAs and 80 ribosomal proteins.
Ribosome biogenesis is a very complex process. First, a
polycistronic pre-rRNA transcript is processed into the 18S
rRNA (component of the 40S subunit) and the 5.8S and
25S/28S rRNAs (component of the 60S subunit). Then,
rRNAs associate with the ribosomal proteins and the 5S
rRNA,whichisindependentlytranscribed,andformanearly
90S particle that is subsequently processed into 66S and
43S preribosomes. Following assembly in the nucleolus, the
preribosomes are exported into the cytoplasm through the
nuclear pore complex as independent entities and additional
maturation steps are necessary to achieve translational
competence. RPS19 is one of the ribosomal proteins that,
together with 18S rRNA, constitute the small 40S subunit
[27].
Recent studies demonstrated that RPS19 not only has a
structural role, as initially thought, but also has additional
functions. The analysis of the RPS19 interactome, by a high
throughput proteomic approach, suggests that RPS19 may
play an important role in rRNA processing, metabolism,
and translation. One hundred and ﬁfty-nine new proteins
interacting with RPS19 have been identiﬁed: NT-Pases,
hydrolases/helicases, isomerases, kinases, splicing factors,
structural constituents of ribosomes, transcription factors,
transferases,transporters,andDNA/RNA-bindingprotein.It
has been demonstrated that RPS19 not only interacts with
other components of the 40S ribosome but also with the
preribosome 90S. Moreover, RPS19 interacts with proteins
important for the transport of the small subunit from the
nucleus to the cytoplasm and also with proteins involved in
the pseudouridylation of rRNA, a process involved in early
stages of ribosome biogenesis [28].
Interference with RPS19 expression in vitro leads to a
reduced maturation of the 40S ribosome subunit, increased
expression of the 60S subunit, reduced 18S rRNA synthesis,
and accumulation of a novel 21S pre-rRNA [1, 29]. The
same results were obtained analyzing bone marrow CD34+
cells and ﬁbroblasts from DBA patients [13, 30]. These data
suggest that RPS19 might be required for a speciﬁc step in
18S rRNA processing from the 21S precursor, highlighting
that RPS19 actively participates in ribosome biogenesis.
Recent works showed that RPS19 haploinsuﬃciency
leads to the posttranscriptional downregulation of other
small subunit ribosomal proteins such as RPS20, RPS21 and
RPS24 compared to large subunit ribosomal proteins. This
has been demonstrated in TF1 cells interfered for RPS19
a n di nl y m p h o b l a s t o i da n dﬁ b r o b l a s tc e l ll i n e sd e r i v e df r o m
RPS19 deﬁcient DBA patients [20, 31] suggesting the impor-
tance of the correct subunits amount and stoichiometry for
ribosome assembly.
2.4. Role of p53 Activation in the Pathogenesis of DBA.
Recent data suggest an important role of p53 family in
the pathogenesis of DBA. The knock-down of RPS19 in
zebraﬁshleadstoerythroidanddevelopmentaldefectswhich
are associated with over-expression of p53 and ΔNp63 [23].
The p53 family plays a crucial role in cell proliferation
and diﬀerentiation during development and p53 activation
promotes cell growth arrest and apoptosis, while ΔNp63
over-expression supports proliferation. It has been hypoth-
esized that an imbalance between p53 and ΔNp63 may aﬀect
the ability of red cell precursors to diﬀerentiate. Moreover,
ΔNp63 has a crucial role in speciﬁcation of nonneural
ectoderm during gastrulation, thus likely contributing to the
craniofacial defects seen in morphants. The phenotype of
RPS19 deﬁcient embryos is alleviated when the expression
of p53 and ΔNp63 is down-regulated [23].
Similar results have been observed when the expression
of RPL11 is knocked-down in zebraﬁsh. Also the loss of
RPL11 leads to developmental defects associated with the
activation of p53 pathway [26].
Interestingly,theactivationofp53hasbeenobservedalso
when the expression of other ribosomal proteins not directly
involved in the pathogenesis of DBA, like RPS8, RPS11,
RPS18, and RPS6, is lost [23, 32], or when the expression of
other factors involved in ribosome biogenesis like Bop1 [33],
bap28 [34], or TCOF is impaired [35]. These data suggest
that impairment of ribosome biogenesis in general leads to
the activation of p53 pathway.
Disruption of the nucleolus, the region where ribosome
biogenesis takes place, also leads to p53 activation [36].
Therefore it has been hypothesized that ribosome biogenesis
impairmentduetomutationsinRPS19couldleadtonucleo-
larstress,p53activation,erythroidfailure,andmalformation
typical of DBA.
2.5. Role of RPS19 during Erythropoiesis. How the hap-
loinsuﬃciency of a ribosomal protein could lead to ery-
throid impairment is still an open question. It has been
hypothesized that immature erythroid progenitors could
be particularly sensitive to ribosomal proteins deﬁciency
with respect to other cell types because of their increased
proliferation rates. High rates of RNA synthesis which
exceeded the cell proliferation rates have been shown in
primary erythroid culture [37]. So these cells could be more
sensitive to ribosome biogenesis impairment due to RPS19
loss than other cell types. This also correlates with the high
expression of RPS19 in the early phases of erythropoiesis
[10, 38].
Furthermore, Sieﬀ and coworker showed for the ﬁrst
time that loss of RPS19 speciﬁcally aﬀects erythropoiesis
as the knock-down of RPS19 in primary murine fetal
liver erythroid cells results in the downregulation of key4 Advances in Hematology
erythroid signaling proteins [37]. Loss of RPS19 decreases
the expression of MYB, a transcription factor critically
important forerythropoiesis, and ofits transcriptional target
KIT. The downregulation of MYB has also been shown using
global gene expression analysis on bone marrow progenitors
from DBA patients [37].
So impairment of ribosome biogenesis during the early
stages of erythropoiesis leads to the deﬁciency of critically
important erythroid transcription factors.
3. Diamond Blackfan Anemiaas a Putative
Disorder of Heme Metabolism
3.1. Feline Leukemia Virus Subgroup C Receptor. Feline
Leukemia Virus subgroup C Receptor (FLVCR1) is a heme
exporter belonging to the major facilitator superfamily
(MFS) of transporters [39]. Overexpression of FLVCR1 in
the rat renal epithelial cell line NRK causes a slight decrease
in intracellular heme concentration while the impairment of
FLVCR1 expression in feline embryonic ﬁbroblasts leads to
increased intracellular heme levels. NRK cells overexpressing
FLVCR1 show an increase in heme export measured using
both the ﬂuorescent heme analog zinc mesoporphyrin and
Fe59-hemin [7].
FLVCR1 is ubiquitously expressed [5]. High levels of
FLVCR1expressionhavebeendetectedinCaco-2andHepG2
cell lines, cancer cell lines, peripheral blood CD34+ stem
cell progenitors, and hematopoietic cell lines with erythroid
features [7].
3.2. Role of FLVCR1 during Erythropoiesis. FLVCR1 has been
initially identiﬁed as the receptor for Feline Leukemia Virus
subgroup C (FeLV C) causing a severe erythroid aplasia in
cats similar to the anemia seen in DBA patients, suggesting
that FLVCR1 plays a fundamental role during erythropoiesis
[40].
FLVCR1 expression is high in early erythroid precursors
and decreases during erythroid diﬀerentiation, similar to
RPS19 expression. Cell lines with undiﬀerentiated erythroid
features like K562 or HEL-DR express high levels of FLVCR1
while it is expressed at low levels in HEL-D, a more mature
cell line with spontaneous hemoglobinization. In the same
way, FLVCR1 is expressed at high levels in CFU-E from
mobilizedperipheralbloodCD34+stemprogenitorcellsand
its expression decreases during erythroid diﬀerentiation in
vitro. Impairment of FLVCR1 function, both in K562 cells
and in lineage-depleted human umbilical cord blood cells,
results in a decreased erythroid diﬀerentiation and increased
apoptosis [7]. In vivo, the loss of FLVCR1 in mice results
in embryonic lethality due to the impairment of deﬁnitive
erythropoiesis. Also when FLVCR1 expression is deleted
postnatally, mice develop severe anemia [5].
3.3. Erythropoiesis and Heme Homeostasis. Heme is a com-
plexofironandprotophorpyrinIXfundamentalforcellbiol-
ogy. Heme is the prosthetic group of many essential proteins
including hemoglobin, myoglobin, and cytochromes. How-
ever, high concentrations of intracellular free heme are toxic,
causing cell oxidative damage through lipid peroxidation. So
the balance between heme biosynthesis, heme utilization for
hemoprotein production, and heme catabolism is controlled
at multiple levels [41].
Moreover, heme is not only a structural component of
hemoproteins but it is also involved in many intracellular
pathways.Intracellularhemeregulatesboththetranscription
and translation of globin chains through interaction with
the transcriptional repressor Bach1 and the heme-regulated
eIF2α kinase (HRI), respectively (Figure 1(a)).
Heme positively regulates the transcription of globin
mRNAs through binding to the transcriptional repressor
Btb and Cnc Homology 1 (Bach1). Under basal condition,
Bach1 heterodimerizes with small Maf transcription factors
and binds to MARE (Maf recognition elements) sequences
inhibiting the transcription of target mRNAs. Heme bind-
ing to Bach1 decreases its aﬃnity to small Maf proteins
and promotes Bach1 nuclear export; small Maf proteins
heterodimerize with Nuclear Factor Erythroid 2-like (Nrf2)
proteins activating the transcription of target genes [42].
So, when intracellular heme concentration increases, the
transcription of globin mRNAs increases.
HRI is a kinase able to phosphorylate the translation
initiation factor eIF2α in a heme-dependent manner. Phos-
phorylation of eIF2 leads to inhibition of protein synthesis.
During erythropoiesis when intracellular heme increases,
heme binding to HRI keeps HRI in an inactive state, thus
allowing protein synthesis. During this stage of erythroid
diﬀerentiation, the main proteins to be synthesized are α-
and β-globin chains and so hemoglobin is formed [43]. The
regulation of HRI activity by intracellular heme allows for
coordination of the synthesis of globin chains with heme
concentration. Imbalance between heme and globin chains
is deleterious to red blood cells and their progenitors as
intracellular free heme promotes oxidative cell damage and
apoptosis. It has been hypothesized that FLVCR1 could
represent an additional control step in this process [7].
Because FLVCR1 expression is high during the earlier stages
of erythropoiesis, it has been suggested that FLVCR1 exports
excess heme out of erythroid progenitors when globin
synthesis is not yet initiated. Then, as erythroid diﬀeren-
tiation proceeds, globin chains synthesis initiates, FLVCR1
expression decreases, and intracellular heme concentration
increases allowing hemoglobin formation (Figure 1(b)).
According to this model, the loss of FLVCR1 expression
leads to increased intracellular free heme, cytotoxicity, and
impaired diﬀerentiation (Figure 1(c)).
3.4. Role of FLVCR1 during Development. In addition to
the erythroid defect, FLVCR1-null embryos display defective
growth and developmental anomalies resembling those
found in DBA [5]: abnormal limb, hand, and digit matura-
tion, ﬂattened faces, and hypertelorism. These data suggest
thatFLVCR1expressionisalsofundamentalforproperorgan
development.
It has been observed that hemoglobin, heme, and
bilirubin have an inhibitory eﬀect on cartilage metabolism
and growth in vitro although the molecular mechanism is
not clear [44–46]. FLVCR1 is expressed at high levels duringAdvances in Hematology 5
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Figure 1: (a) Multiple roles of heme during erythroid cell diﬀerentiation. (b) Role of FLVCR1 during erythroid diﬀerentiation. (c) A model
to explain how both FLVCR1, and RPS19 deﬁciencies may result in the failure of erythroid diﬀerentiation.6 Advances in Hematology
development in the yolk sac and placenta [5]. It is possible
that beyond a role in erythropoiesis, FLVCR1 could be also
involved in maternal-fetus heme exchange. If so, we can
hypothesize that the lack of FLVCR1 during development
may determine a heme overload condition in the embryo
and, consequently, an inhibition of cartilage development,
resulting in malformations.
3.5. Links between FLVCR1 and DBA. It is now clear that
DBA is a clinically heterogeneous disorder and no clear
genotype-phenotype correlation has been found. Congenital
malformation is constitutional in most patients, but the type
and degree of severity of these anomalies is also diﬀerent
among DBA patients aﬀected by the same mutation. In the
same way there is no correlation between genotype and
cancer predisposition or response to therapies. Mutations
in ribosomal proteins account for about half of DBA cases,
but the molecular genetics of the remaining cases is still
unknown, suggesting the existence of other DBA genes
or unidentiﬁed modiﬁers that modulate the phenotype of
DBA.
Interestingly, FLVCR1-null mice display a phenotype
very close to DBA. Impairment of erythropoiesis occurs at
the same stage as that seen in DBA patients, and also the
kind of malformations seen in FLVCR1-null mice are very
similar to the congenital abnormalities described in DBA
patients.
Human FLVCR1 has been mapped by radiation hybrid
mapping to chromosome 1q31.3. Apart from the transcrip-
tion factor ATF3, no other genes have been mapped to this
chromosome region. It is intriguing that rearrangement of
the distal region on chromosome 1q has been described in a
patient with DBA. Mutations in FLVCR1 have been searched
in a small group of multiplex DBA families with disease
linkage to 1q31 but no mutations have been identiﬁed [8].
Alternatively spliced isoforms of FLVCR1 have been
identiﬁed in immature bone marrow erythroid cells of some
DBA patients negative for RPS19 gene mutations. Four
diﬀerent FLVCR1 isoforms result from the deletion of exon
2 or exon 3 alone or in combination with exon 6 [47].
Splicing of FLVCR1 exon 3 or exon 6 causes in-
frame mutations that encode potential proteins with major
deletions. Splicing of exon 2 causes a frame-shift mutation
resulting in a premature stop codon and potentially encodes
a truncated isoform of the protein.
In vitro, overexpression of deleted exon 3 or exon
6 FLVCR1 isoforms leads to phenotypes that are weakly
susceptible to FeLV-C infection, indicating that FLVCR1
function is impaired. These isoforms are expressed at
lower levels than normal FLVCR1 and are mislocalized:
while canonical FLVCR1 is expressed at the cell membrane,
alternative spliced FLVCR1 isoforms localize intracellularly.
Moreover, immature erythroid cells from DBA patients show
a decreased expression of FLVCR1 mRNA and an enhance-
ment of alternative spliced transcripts. It is interesting that
RPS19 interference in K562 cells results in an increase
of FLVCR1 alternative splicing, establishing the ﬁrst link
between RPS19 and FLVCR1 in the pathogenesis of DBA
[47].
4. Conclusions
DBA is a clinically heterogeneous disorder characterized by
hypoplastic anemia associated with congenital malforma-
tions, and cancer predisposition. The molecular mechanisms
underlying the pathogenesis of DBA are still not completely
understood. Mutations in RPS19 cause an impairment of
ribosome biogenesis and protein synthesis but how this leads
to erythroid failure, congenital malformations and cancer
is unknown. It has been hypothesized that impairment of
ribosome biogenesis leads to nucleolar disorganization and
activation of the p53 family.
It is intriguing to note the similarity between the
phenotype of FLVCR1-null embryos and DBA. It has been
hypothesized that the loss of both FLVCR1 and RPS19
could converge on the same pathway. Loss of FLVCR1
causes increased intracellular heme levels during a stage of
erythroid diﬀerentiation in which globin chains synthesis
is not yet initiated. The haploinsuﬃciency of RPS19 leads
to impaired ribosome biogenesis and therefore protein
synthesis.Asglobinchainsarethemajorproteinssynthesized
during erythroid diﬀerentiation, there is an increase in
intracellular free heme. In both cases, high intracellular
heme concentration would result in the block of erythroid
diﬀerentiation and apoptosis (Figure 1(c)). This hypothesis
clearly explains the erythroid phenotype but not how RPS19
or FLVCR1 deﬁciency leads to congenital malformations. As
mentioned earlier, heme is a potent inhibitor of cartilage
growth and metabolism. Thus, even in this case it is possible
to speculate that heme overload resulting from FLVCR1 gene
function impairment and reduced protein synthesis due to
ribosomal protein genes mutations may generate the same
phenotype,thatis,skeletalmalformation.Interestingly,ithas
been reported that perichondrial zone expresses high levels
of genes involved in protein synthesis including RPL35a and
RPS6, as well as the hemoglobin beta2 gene.
Finally, the work of Rey and colleagues suggested a direct
relationship between RPS19 and FLVCR1 [47]. Interference
with RPS19 results in a decreased expression of FLVCR1
and in an increased level of alternative spliced isoforms of
FLVCR1, with compromised function. It could be speculated
that RPS19 is able to directly or indirectly regulate the
expression of FLVCR1 but the molecular details of this
relationship are yet to be understood. Moreover, nothing is
known about the proteins interacting with FLVCR1 and so
we cannot exclude the fact that RPS19 and FLVCR1 may
share common downstream interactors.
The availability of cellular and animal models for
studying ribosomal proteins and FLVCR1 gene function
constitutes the basis for future work aimed at elucidating the
molecular pathogenetic mechanism of DBA.
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